Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study
- PMID: 28552471
- DOI: 10.1016/j.ijantimicag.2017.03.009
Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study
Abstract
The aim of this study was to determine the epidemiology and risk factors associated with community-onset urinary tract infections (CO-UTIs) due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae (ESBL-Kp). A cohort study including all consecutive patients with K. pneumoniae CO-UTI identified from January 2010 to December 2014 was conducted. Patients with CO-UTI due to ESBL-Kp were then included as cases in a retrospective case-control-control study; controls were outpatients with CO-UTI caused by non-ESBL-producing Escherichia coli and K. pneumoniae (non-ESBL-Ec and non-ESBL-Kp, respectively). Each control was matched in a 2:1 ratio according to patient age, sex and year of isolation. Genotyping confirming ESBL was performed by multiplex PCR and sequencing. The prevalence of ESBL-Kp CO-UTIs, calculated among all K. pneumoniae CO-UTIs, increased from 2.4% in 2010 to 10.3% in 2014 (P = 0.01). Among cases, 63.8% were truly community-acquired, and CTX-M-15 was the predominant β-lactamase enzyme type (79.3%). A total of 83 cases and 319 controls were studied. Being a nursing home resident [odds ratio (OR) = 8.8, 95% confidence interval (CI) 2.6-29.4] and previous cephalosporin use (OR = 4.01, 95% CI 1.8-9.2) were risk factors independently associated with CO-UTI due to ESBL-Kp. In conclusion, the prevalence of CO-UTIs due to ESBL-Kp is increasing. In most cases, ESBL-Kp CO-UTIs are community-acquired and produce CTX-M-15 β-lactamase. Exposure to cephalosporins and being a nursing home resident were risk factors associated with ESBL-Kp CO-UTIs. CTX-M-15-producing K. pneumoniae isolates are emerging in the community.
Keywords: CTX-M-15; Community-onset; Extended-spectrum β-lactamase; Klebsiella pneumoniae; Urinary tract infection.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
Similar articles
-
New Delhi metallo-β-lactamase and extended spectrum β-lactamases co-producing isolates are high in community-acquired urinary infections in Assam as detected by a novel multiplex polymerase chain reaction assay.Indian J Med Microbiol. 2016 Apr-Jun;34(2):173-82. doi: 10.4103/0255-0857.176853. Indian J Med Microbiol. 2016. PMID: 27080768
-
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.J Antimicrob Chemother. 2006 Apr;57(4):780-3. doi: 10.1093/jac/dkl035. Epub 2006 Feb 21. J Antimicrob Chemother. 2006. PMID: 16492721
-
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31. Int Urol Nephrol. 2015. PMID: 26026972
-
Prevalence of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: First systematic review and meta-analysis from Iran.J Glob Antimicrob Resist. 2019 Sep;18:12-21. doi: 10.1016/j.jgar.2019.01.020. Epub 2019 Jan 24. J Glob Antimicrob Resist. 2019. PMID: 30685458
-
A systematic review and meta-analysis on the prevalence of extended-spectrum beta-Lactamase-Producing Klebsiella Pneumonia in Nigeria.Afr Health Sci. 2024 Sep;24(3):30-40. doi: 10.4314/ahs.v24i3.5. Afr Health Sci. 2024. PMID: 40777963 Free PMC article. Review.
Cited by
-
Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0055221. doi: 10.1128/AAC.00552-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34001510 Free PMC article.
-
From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.Antibiotics (Basel). 2022 Feb 4;11(2):201. doi: 10.3390/antibiotics11020201. Antibiotics (Basel). 2022. PMID: 35203803 Free PMC article.
-
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.J Antimicrob Chemother. 2022 Dec 23;78(1):93-100. doi: 10.1093/jac/dkac359. J Antimicrob Chemother. 2022. PMID: 36272135 Free PMC article.
-
Clinical and Economic Impact of Community-Onset Urinary Tract Infections Caused by ESBL-Producing Klebsiella pneumoniae Requiring Hospitalization in Spain: An Observational Cohort Study.Antibiotics (Basel). 2021 May 15;10(5):585. doi: 10.3390/antibiotics10050585. Antibiotics (Basel). 2021. PMID: 34063338 Free PMC article.
-
Development and validation of a nomogram-based risk prediction model for carbapenem-resistant Klebsiella pneumoniae in hospitalized patients.Microbiol Spectr. 2025 Jan 7;13(1):e0217024. doi: 10.1128/spectrum.02170-24. Epub 2024 Dec 6. Microbiol Spectr. 2025. PMID: 39641574 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical